Astrazeneca Scores Milestone Victory In Oncology


AstraZeneca stock was treading water on Friday despite the pharma titan receiving full approval from the U.S. Food and Drug Administration for a key drug within its oncology portfolio and announcing a licensing deal over another cancer treatment. The FDA granted Tagrisso 80mg once-daily tablets full approval for treatment of a T790M mutation-positive non-small cell lung cancer , after it was found superior than the one other available treatment - chemotherapy - for the condition.



from Biotech News